Product Name,Synonyms,CAS Number,M. Wt,Target,Pathway,Biological Activity,Formula,Solubility,Concentration,Research Area,Clinical Information,SMILES
Telatinib,Bay 57-9352,332012-40-5,409.83,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.",C20H16ClN5O3,DMSO : ≥ 46 mg/mL (112.24 mM),10mM,Cancer,Phase 2,O=C(C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1)NC
Cinobufotalin,,1108-68-5,458.54,Others,Others,"Cinobufotalin is a cardiotonic steroids or bufadienolides, is extracted from the skin secretions of the giant toads. Cinobufotalin has been used as a cardiotonic, diuretic and a hemostatic agent, Cinobufotalin is also a potential anti-lung cancer agent[1].",C26H34O7,DMSO : 125 mg/mL (272.60 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]([C@@H](C(C=C1)=COC1=O)[C@H]2OC(C)=O)(CC[C@@]3([H])[C@@]4([H])CC[C@@]5(O)[C@@]3(CC[C@H](O)C5)C)[C@@]64[C@@H]2O6
Aspirin,Acetylsalicylic acid; ASA,50-78-2,180.16,Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].",C9H8O4,DMSO : 100 mg/mL (555.06 mM; Need ultrasonic); H2O : 3.12 mg/mL (17.32 mM; ultrasonic and warming and heat to 37°C),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(C1=C(OC(C)=O)C=CC=C1)=O
Falnidamol,BIBX 1382,196612-93-8,387.84,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].",C18H19ClFN7,DMSO : 31.25 mg/mL (80.57 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,ClC1=CC(NC2=NC=NC3=CN=C(NC(CC4)CCN4C)N=C23)=CC=C1F
PH-797804,,586379-66-0,477.3,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC50=26 nM and Ki=5.8 nM for p38α; Ki=40 nM for p38β) and does not inhibit JNK2.",C22H19BrF2N2O3,DMSO : 50 mg/mL (104.76 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 2,O=C(C1=CC=C(C(N2C(C)=CC(OCC3=CC=C(C=C3F)F)=C(C2=O)Br)=C1)C)NC
N-Acetylputrescine hydrochloride,,18233-70-0,166.65,Endogenous Metabolite,Metabolic Enzyme/Protease,"N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD)[1][2][3][4].",C6H15ClN2O,H2O : 200 mg/mL (1200.12 mM; Need ultrasonic); DMSO : ≥ 125 mg/mL (750.08 mM),10mM,Cancer; Neurological Disease,Phase 2,CC(NCCCCN)=O.Cl
Estramustine,,2998-57-4,440.4,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Estramustine is an antineoplastic agent. Estramustine depolymerizes microtnbules by binding to tubulin 1, exhibits antimitotic activity with an IC50 value of ~16 μM for mitosis of DU 145 cells. Estramustine blocks cells at mitosis in prostate tumor xenografts[1].",C23H31Cl2NO3,DMSO : 100 mg/mL (227.07 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@@]12[C@](CC[C@@H]2O)([H])[C@@]3([H])[C@@](CC1)([H])C4=CC=C(OC(N(CCCl)CCCl)=O)C=C4CC3
Cenisertib,AS-703569; R-763,871357-89-0,451.54,Akt; Aurora Kinase; Bcr-Abl; FLT3; STAT,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3].",C24H30FN7O,DMSO : 250 mg/mL (553.66 mM; Need ultrasonic),10mM,Cancer,Phase 1,[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]
Estramustine (phosphate sodium),,52205-73-9,564.35,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate sodium can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer[1][2][3].",C23H30Cl2NNa2O6P,H2O : 62.5 mg/mL (110.75 mM; Need ultrasonic); DMSO : 5 mg/mL (8.86 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology,Launched,O=C(N(CCCl)CCCl)OC1=CC2=C(C=C1)[C@@]3([H])CC[C@@]4(C)[C@](CC[C@@H]4OP(O[Na])(O[Na])=O)([H])[C@]3([H])CC2
CPL304110,,1627826-19-0,446.54,FGFR,Protein Tyrosine Kinase/RTK,"CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively[1].",C25H30N6O2,DMSO : 100 mg/mL (223.94 mM; Need ultrasonic),10mM,Cancer,Phase 1,CN(CC1)CCN1C2=CC3=C(N=C(C4=NNC(CCC5=CC(OC)=CC(OC)=C5)=C4)N3)C=C2
Pemigatinib,INCB054828,1513857-77-6,487.5,FGFR,Protein Tyrosine Kinase/RTK,"Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma[1][2].",C24H27F2N5O4,DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4
Vepafestinib,TAS0953/HM06,2129515-96-2,474.55,Apoptosis; RET,Apoptosis; Protein Tyrosine Kinase/RTK,"Vepafestinib (TAS0953/HM06) is a next-generation brain-penetrant, selective and orally active RET inhibitor with an IC50 value of 0.33 nM. Vepafestinib inhibits the phosphorylation of RET and its downstream signaling pathways, thus blocking the growth and signal transduction of tumor cells and inducing cell cycle arrest and apoptosis. Vepafestinib can be used in the research of various RET-driven cancers, such as non-small cell lung cancer, thyroid cancer and other disease areas[1].",C26H30N6O3,DMSO : 50 mg/mL (105.36 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(C#CCN2CCOCC2)N(C3(C)CC3)C4=NC=NC(N)=C41)NC5=CC=C(COC)C=C5
Ensartinib (dihydrochloride),X-396 (dihydrochloride),2137030-98-7,634.36,Anaplastic lymphoma kinase (ALK); c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.",C26H29Cl4FN6O3,H2O : 33.33 mg/mL (52.54 mM; Need ultrasonic); DMSO : 35.71 mg/mL (56.29 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3.Cl.Cl
LY2334737,,892128-60-8,389.39,Enterovirus; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects[1][2].,C17H25F2N3O5,DMSO : ≥ 100 mg/mL (256.81 mM),10mM,Cancer; Infection,Phase 1,OC[C@@H]1[C@H](C(F)(F)[C@H](N2C(N=C(C=C2)NC(C(CCC)CCC)=O)=O)O1)O
Tinengotinib,TT 00420,2230490-29-4,394.86,Aurora Kinase; FGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment[1][2].",C20H19ClN6O,DMSO : 50 mg/mL (126.63 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,ClC1=C(C2=NC3=C(C)NN=C3NC4=C2C=NC(N5CCOCC5)=C4)C=CC=C1
Doxorubicin (hydrochloride),Hydroxydaunorubicin (hydrochloride); ADR,25316-40-9,579.98,ADC Payload; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].",C27H30ClNO11,DMSO : 25 mg/mL (43.10 mM; ultrasonic and warming and heat to 60°C); H2O : 50 mg/mL (86.21 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Launched,COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl
Gatifloxacin (hydrochloride),AM-1155 (hydrochloride); BMS-206584 (hydrochloride); PD135432 (hydrochloride),121577-32-0,411.86,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.,C19H23ClFN3O4,DMSO : 4 mg/mL (9.71 mM; ultrasonic and warming and heat to 60°C); H2O : 10 mg/mL (24.28 mM; Need ultrasonic),10mM,Infection,Launched,CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC)C1.Cl
Nedometinib,NFX-179,2252314-46-6,470.24,MEK; p38 MAPK; PERK,Cell Cycle/DNA Damage; MAPK/ERK Pathway,"Nedometinib (NFX-179) is a specific MEK1 inhibitor with an IC50 of 135 nM. Nedometinib inhibits p-ERK, MAPK. Nedometinib exerts anticancer activity against squamous cell carcinoma. Nedometinib can be used for research in dermatosis, neurofibromatosis[1][2].",C17H16FIN4O3,DMSO : 100 mg/mL (212.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(NC2=CC=C(C=C2F)I)N(C)C3=C1C=CC=N3)NOCCO
Sulfatinib,Surufatinib; HMPL-012,1308672-74-3,480.58,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.",C24H28N6O3S,DMSO : ≥ 100 mg/mL (208.08 mM),10mM,Cancer,Launched,O=S(CC1=CC=CC(NC2=NC=CC(OC3=CC4=C(NC(C)=C4)C=C3)=N2)=C1)(NCCN(C)C)=O
Muramyl dipeptide,MDP,53678-77-6,492.48,NOD-like Receptor (NLR); p38 MAPK,Immunology/Inflammation; MAPK/ERK Pathway,"Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist[1][2].",C19H32N4O11,H2O : 50 mg/mL (101.53 mM; Need ultrasonic); DMSO : 100 mg/mL (203.05 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 3,CC(N[C@@H](C=O)[C@H]([C@H](O)[C@H](O)CO)O[C@H](C)C(N[C@@H](C)C(N[C@@H](C(N)=O)CCC(O)=O)=O)=O)=O
Pexmetinib,ARRY-614,945614-12-0,556.63,Autophagy; p38 MAPK; Tie,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.",C31H33FN6O3,DMSO : ≥ 125 mg/mL (224.57 mM),10mM,Cancer,Phase 2,O=C(NCC1=CC(F)=CC=C1OC2=CC3=C(N(CCO)N=C3)C=C2)NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5
Asiaticoside,,16830-15-2,959.12,Apoptosis; Endogenous Metabolite; p38 MAPK; Reactive Oxygen Species (ROS); TGF-beta/Smad,Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt; TGF-beta/Smad,"Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.",C48H78O19,DMSO : 100 mg/mL (104.26 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Cancer,Phase 3,C[C@@H]1CC[C@@]2(C(O[C@@H]3O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@]5([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@H]3O)=O)[C@@](C6=CC[C@@]([C@](C[C@@H](O)[C@H](O)[C@]7(CO)C)(C)[C@@]7([H])CC8)([H])[C@]8(C)[C@]6(C)CC2)([H])[C@H]1C
Foretinib,XL880; GSK1363089; GSK089; EXEL-2880,849217-64-7,632.65,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. ,C34H34F2N4O6,DMSO : 75 mg/mL (118.55 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O
Ombrabulin,AVE8062; AC7700,181816-48-8,402.44,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Ombrabulin (AVE8062) is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the tubulin cytoskeleton of endothelial cells.",C21H26N2O6,DMSO : 100 mg/mL (248.48 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C(NC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO
Amonafide,AS1413,69408-81-7,283.33,Topoisomerase,Cell Cycle/DNA Damage,Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.,C16H17N3O2,DMSO : 41.67 mg/mL (147.07 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1N(C(C2=CC(N)=CC3=CC=CC1=C23)=O)CCN(C)C
Burixafor (hydrobromide),TG-0054 (hydrobromide),1191450-19-7,769.01,CXCR; VEGFR,GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK,"Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses[1][2][3].",C27H51N8O3P.5/2HBr,H2O : 50 mg/mL (65.02 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease,Phase 2,NC1=CC(N2CCN(CCP(O)(O)=O)CC2)=NC(NC[C@H]3CC[C@H](CNCCCNC4CCCCC4)CC3)=N1.[H]Br
Carboxyamidotriazole,L-651582; CAI,99519-84-3,424.67,Calcium Channel; NF-κB; NO Synthase; p38 MAPK,Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB,"Carboxyamidotriazole (L-651582) is an orally active cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole inhibits NF-κB, MAPK activation and NO production. Carboxyamidotriazole has anti-angiogenic and anti-inflammatory activities. Carboxyamidotriazole has anticancer activity against liver cancer, lung cancer and leukemia[1][2][3][4][5][6][7][8][9][10][11][12][13].",C17H12Cl3N5O2,DMSO : 100 mg/mL (235.48 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Phase 3,O=C(C1=C(N)N(CC2=CC(Cl)=C(C(C3=CC=C(Cl)C=C3)=O)C(Cl)=C2)N=N1)N
BNC105,,945771-74-4,372.37,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.,C20H20O7,DMSO : 25 mg/mL (67.14 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC1=CC(C(C2=C(C)OC3=C(O)C(OC)=CC=C23)=O)=CC(OC)=C1OC
GSK-690693,,937174-76-0,425.48,Akt; AMPK; Autophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3].",C21H27N7O3,DMSO : 20 mg/mL (47.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,CC(O)(C)C#CC1=NC=C(OC[C@@H]2CNCCC2)C3=C1N=C(C4=NON=C4N)N3CC
Repotrectinib,TPX-0005,1802220-02-5,355.37,Anaplastic lymphoma kinase (ALK); ROS Kinase; Trk Receptor,Neuronal Signaling; Protein Tyrosine Kinase/RTK,Repotrectinib (TPX-0005) is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib has anti-cancer activity[1][2].,C18H18FN5O2,DMSO : 25 mg/mL (70.35 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NC[C@H](C)OC2=CC=C(F)C=C2[C@@H](C)NC3=NC4=C1C=NN4C=C3
Golotimod (hydrochloride),SCV 07 (hydrochloride); Gamma-D-glutamyl-L-tryptophan (hydrochloride),1029401-59-9,369.8,Bacterial; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].",C16H20ClN3O5,H2O : 150 mg/mL (405.62 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cancer,Phase 2,O=C(CC[C@@](N)(C(O)=O)[H])NC([H])(C(O)=O)CC1=CNC2=C1C=CC=C2.Cl
Procarbazine (Hydrochloride),,366-70-1,257.76,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"Procarbazine Hydrochloride is an orally active alkylating agent, with anticancer activity. Procarbazine Hydrochloride can be used in Hodgkin's disease research[1][2].",C12H20ClN3O,H2O : 100 mg/mL (387.96 mM; Need ultrasonic); DMSO : 16.67 mg/mL (64.67 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC(C)C)C1=CC=C(CNNC)C=C1.Cl
SYHA1813,,1807466-30-3,410.44,c-Fms; VEGFR,Protein Tyrosine Kinase/RTK,SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM[1].,C25H19FN4O,DMSO : 100 mg/mL (243.64 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NNC2=C1C(C3=CC=C4C(C=CC=C4C(NC5=CC=C(F)C(C)=C5)=O)=C3)=CC=C2
Aurintricarboxylic acid,,4431-00-9,422.34,Apoptosis; Influenza Virus; MicroRNA; P2X Receptor; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Membrane Transporter/Ion Channel,"Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively[1]. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase[2]. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis[3]. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway[4]. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM[5]. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 μM[6].",C22H14O9,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 125 mg/mL (295.97 mM; Need ultrasonic); NH4OH : 10 mg/mL (23.68 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Neurological Disease,Phase 2,O=C(C=C/1)C(C(O)=O)=CC1=C(C2=CC(C(O)=O)=C(O)C=C2)\C3=CC(C(O)=O)=C(O)C=C3
Capmatinib (dihydrochloride),INC280 (dihydrochloride); INCB28060 (dihydrochloride),1197376-85-4,485.34,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].",C23H19Cl2FN6O,DMSO : 5.83 mg/mL (12.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.Cl.Cl
Pelitinib,EKB-569; WAY-EKB 569,257933-82-7,467.92,EGFR; Src,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. ",C24H23ClFN5O2,DMSO : 25 mg/mL (53.43 mM; Need ultrasonic),10mM,Cancer,Phase 2,N#CC1=C(C2=CC(NC(/C=C/CN(C)C)=O)=C(OCC)C=C2N=C1)NC3=CC(Cl)=C(C=C3)F
Ifupinostat,BEBT-908,1235449-52-1,507.57,PI3K,PI3K/Akt/mTOR,"Ifupinostat is a selective PI3Kα inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC50<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC50≤1 μM) .",C23H25N9O3S,DMSO : ≥ 37 mg/mL (72.90 mM),10mM,Cancer,Phase 3,CN(CC1=CC(N=C(C2=CN=C(NC)C=C2)N=C3N4CCOCC4)=C3S1)C5=NC=C(C(NO)=O)C=N5
Naquotinib (mesylate),ASP8273 (mesylate),1448237-05-5,658.81,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.",C31H46N8O6S,DMSO : 12.5 mg/mL (18.97 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,O=C(C1=NC(CC)=C(O[C@H]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N.CS(=O)(O)=O
Itacnosertib,TP-0184,1628870-27-8,468.55,Akt; Anaplastic lymphoma kinase (ALK); FLT3; JAK; mTOR; PI3K; STAT; TGF-beta/Smad; TGF-β Receptor,Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad,"Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib exhibits anti-leukemic activity[1][2].",C26H28N8O,DMSO : 12.5 mg/mL (26.68 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1CCN(C2=CC=C(NC3=NC=CC(NC4=CC=CN=C4C5=NC=CC=C5)=N3)C=C2OC)CC1
Ombrabulin (hydrochloride),AVE8062 (hydrochloride); AC7700 (hydrochloride),253426-24-3,438.9,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Ombrabulin hydrochloride is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the tubulin cytoskeleton of endothelial cells.",C21H27ClN2O6,DMSO : 100 mg/mL (227.84 mM; Need ultrasonic); H2O : 20 mg/mL (45.57 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C(NC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO.[H]Cl
Naporafenib,LXH254,1800398-38-2,502.49,Bcr-Abl; p38 MAPK; Raf,MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively[1][2].",C25H25F3N4O4,DMSO : 100 mg/mL (199.01 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=CC=C(NC(C2=CC(C(F)(F)F)=NC=C2)=O)C=C1C3=CC(N4CCOCC4)=NC(OCCO)=C3
Alofanib,RPT835,1612888-66-0,413.4,Apoptosis; FGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity[1][2].,C19H15N3O6S,DMSO : ≥ 30.1 mg/mL (72.81 mM),10mM,Cancer; Cardiovascular Disease,Phase 1,O=C(O)C1=CC=CC(S(=O)(NC2=CC(C3=CC=CN=C3)=C(C)C=C2[N+]([O-])=O)=O)=C1
NT219,,1198078-60-2,412.26,Insulin Receptor; STAT,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases[1].,C16H14BrNO5S,DMSO : ≥ 100 mg/mL (242.57 mM),10mM,Cancer,Phase 2,OC(C=C1CNC(/C=C/C2=C(C(O)=C(C=C2)O)Br)=S)=C(C(O)=C1)O
Oleanolic acid,Oleanic acid; Caryophyllin,508-02-1,456.7,Autophagy; Endogenous Metabolite; HIV; MAP3K,Anti-infection; Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease,Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.,C30H48O3,DMSO : 5 mg/mL (10.95 mM; Need ultrasonic); DMF : 45.45 mg/mL (99.52 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,C[C@]([C@@]1([H])[C@]2(CC[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C
PD-166866,,192705-79-6,396.44,Autophagy; FGFR,Autophagy; Protein Tyrosine Kinase/RTK,PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM.,C20H24N6O3,DMSO : 3.33 mg/mL (8.40 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 4,O=C(NC(C)(C)C)NC1=NC2=NC(N)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3
Oritinib,SH-1028,2035089-28-0,539.67,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively[1].",C31H37N7O2,DMSO : 125 mg/mL (231.62 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC(NC2=NC(C3=C(CCCC4)N4C5=C3C=CC=C5)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
PF 477736,PF 00477736,952021-60-2,419.48,Aurora Kinase; CDK; c-Fms; Checkpoint Kinase (Chk); FGFR; FLT3; RET; Src; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3,  and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo[1][2].",C22H25N7O2,DMSO : 100 mg/mL (238.39 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C([C@@H](C1CCCCC1)N)NC2=CC3=C(C(C=NNC4=O)=C(N3)C5=CN(N=C5)C)C4=C2
Cediranib (maleate),AZD-2171 maleate,857036-77-2,566.58,Autophagy; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.",C29H31FN4O7,DMSO : ≥ 45 mg/mL (79.42 mM); H2O : 2 mg/mL (3.53 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(O)/C=C\C(O)=O.FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5
Enozertinib (hemihydrate),ORIC-114 (hemihydrate),,669.77,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Enozertinib (ORIC-114) hemihydrate is the inhibitor for EGFR that exhibits antineoplastic activity[1].,C35H42F2N8O3.1/2H2O,,10mM,Cancer,Phase 2,C=CC(NC1=C(N2CCC(N3CCN(C4CC4)CC3)CC2)C=C(C(NC5=NC=NC(N6[C@@H](C7=CC(F)=CC(F)=C7)CCO6)=C5)=C1)OC)=O.O.[0.5]
CA-170,,1673534-76-3,360.32,PD-1/PD-L1,Immunology/Inflammation,CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].,C12H20N6O7,DMSO : 28.5 mg/mL (79.10 mM; Need ultrasonic and warming),10mM,Inflammation/Immunology; Cancer,Phase 1,C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O
Histamine (phosphate),Histamine diphosphate,51-74-1,307.14,Akt; Apoptosis; Endogenous Metabolite; Histamine Receptor; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma[1][2][3][4][5][6][7].",C5H15N3O8P2,H2O : 100 mg/mL (325.58 mM; Need ultrasonic); DMSO : 1.43 mg/mL (4.66 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease,Launched,NCCC1=CNC=N1.O=P(O)(O)O.O=P(O)(O)O
BMS-599626 (Hydrochloride),AC480 (Hydrochloride),873837-23-1,567.01,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy[1][2].",C27H28ClFN8O3,DMSO : 100 mg/mL (176.36 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(OC[C@H]1NCCOC1)NC2=CN(C3=C2C)N=CN=C3NC4=CC5=C(C=C4)N(CC6=CC(F)=CC=C6)N=C5.Cl
DRF-1042,,200619-13-2,408.4,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype[1][2].,C22H20N2O6,DMSO : 50 mg/mL (122.43 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1[C@](CC)(C2=C(C(N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)=O)CO1)O
RGX-104 (hydrochloride),Abequolixron (hydrochloride),610318-03-1,632.54,LXR,Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,RGX-104 hydrochloride is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.,C34H34Cl2F3NO3,DMSO : 125 mg/mL (197.62 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 1,O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1.Cl
Ningetinib Tosylate,,1394820-77-9,728.79,c-Met/HGFR; TAM Receptor; VEGFR,Protein Tyrosine Kinase/RTK,"Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.",C38H37FN4O8S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble); DMSO : 33.33 mg/mL (45.73 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=CC=C(S(=O)(O)=O)C=C1.CC2=C(C(NC3=CC(F)=C(OC4=CC=NC5=C4C=CC(OCC(C)(O)C)=C5)C=C3)=O)C(N(C6=CC=CC=C6)N2C)=O
Lomustine,CCNU; NSC 79037,13010-47-4,233.7,Apoptosis; Autophagy; DNA Alkylator/Crosslinker,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Lomustine (CCNU; NSC 79037) is a DNA alkylating agent, with antitumor activity.",C9H16ClN3O2,DMSO : ≥ 100 mg/mL (427.90 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(NC1CCCCC1)N(CCCl)N=O
Perindopril,S-9490,82834-16-0,368.47,Angiotensin-converting Enzyme (ACE); NF-κB; Sirtuin; STAT,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt,"Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension[1][2][3][4].",C19H32N2O5,H2O : 100 mg/mL (271.39 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer; Neurological Disease; Cardiovascular Disease,Launched,O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC)C)=O)[C@@]2([H])CCCC[C@@]2([H])C1)O
Anethole trithione,,532-11-6,240.36,mAChR,GPCR/G Protein; Neuronal Signaling,"Anethole trithione, a sulfur heterocyclic choleretic, is a bile secretion-stimulating agent. Anethole trithione enhances salivary secretion and increases mAChRs, and can be used for dry mouth research[1][2].",C10H8OS3,DMSO : 12.5 mg/mL (52.01 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,S=C1SSC(C2=CC=C(OC)C=C2)=C1
Utidelone,Epothilone D; UTD1; KOS 862,189453-10-9,491.68,Antibiotic; Bacterial; Fungal; Microtubule/Tubulin,Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton,Utidelone (Epothilone D) is a potent microtubule stabilizer.,C27H41NO5S,DMSO : ≥ 100 mg/mL (203.38 mM),10mM,Cancer; Infection,Phase 2,O=C1C[C@H](O)C(C)(C)C([C@H](C)[C@@H](O)[C@@H](C)CCC/C(C)=C/C[C@@H](/C(C)=C/C2=CSC(C)=N2)O1)=O
SB-743921 (hydrochloride),,940929-33-9,553.52,Kinesin,Cell Cycle/DNA Damage; Cytoskeleton,"SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM.",C31H34Cl2N2O3,DMSO : ≥ 100 mg/mL (180.66 mM); H2O : 10 mg/mL (18.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,ClC1=CC2=C(C(C(CC3=CC=CC=C3)=C([C@@H](C(C)C)N(C(C4=CC=C(C=C4)C)=O)CCCN)O2)=O)C=C1.Cl
Fruquintinib,HMPL-013,1194506-26-7,393.39,VEGFR,Protein Tyrosine Kinase/RTK,"Fruquintinib (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.",C21H19N3O5,DMSO : 5 mg/mL (12.71 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=C(C)OC2=CC(OC3=C4C=C(OC)C(OC)=CC4=NC=N3)=CC=C12)NC
MRT-2359,,2803881-11-8,495.38,Apoptosis,Apoptosis,"MRT-2359 is a potent, orally active and selective GSPT1 depressant (IC50: >30 nM and <300 nM) that specifically induces apoptosis dependent on protein translation. MRT-2359 exhibits significant and preferred anti-proliferative activity in a variety of cancer cell lines, especially MYC-driven cell lines, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with high expression of N-Myc or L-Myc. MRT-2359 inhibits the growth of drug-resistant NSCLC and SCLC cells, making it suitable for cancer research[1][2][3][4][5].",C22H17F4N3O6,DMSO : 100 mg/mL (201.87 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(OC(F)(F)F)=CC=C1F)OCC2=CC=C3C(C(N(C4C(NC(CC4)=O)=O)C3)=O)=C2
Pirenzepine,LS 519 (free base); Pirenzepin; Gastrozepin,28797-61-7,351.4,mAChR,GPCR/G Protein; Neuronal Signaling,"Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells[1][2].",C19H21N5O2,DMSO : 100 mg/mL (284.58 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease,Launched,O=C1NC2=CC=CN=C2N(C(CN3CCN(C)CC3)=O)C4=CC=CC=C14
Serabelisib,MLN1117; INK1117; TAK-117,1268454-23-4,363.37,PI3K,PI3K/Akt/mTOR,Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.,C19H17N5O3,DMSO : 6.4 mg/mL (17.61 mM; Need ultrasonic and warming),10mM,Cancer,Phase 2,O=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5
Paclitaxel,,33069-62-4,853.91,ADC Payload; Apoptosis; Autophagy; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].,C47H51NO14,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (117.11 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Launched,O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
RGB-286638 (free base),,784210-88-4,545.63,CDK; GSK-3; JAK; MEK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of  3, 5, 50, and 54 nM.",C29H35N7O4,DMSO : 2.6 mg/mL (4.77 mM; Need ultrasonic); Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),2mM,Cancer,Phase 1,O=C(NN1CCOCC1)NC2=CC=CC(C3=C4C(C5=CC=C(CN6CCN(CCOC)CC6)C=C5)=NN3)=C2C4=O
Daraxonrasib,RMC-6236; RAS-IN-2,2765081-21-6,811.05,PERK; Ras,Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway,"RMC-6236 is an orally active, non-covalent RAS (ON) inhibitor. RMC-6236 disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. RMC-6236 inhibits pERK. RMC-6236 has anti-tumor activity against KRAS mutant tumors[1][2][3].",C44H58N8O5S,DMSO : 100 mg/mL (123.30 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC(COC([C@H]1NN(C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)CCC1)=O)(C)CC5=[C@@](N(CC)C6=C5C=C3C=C6)[C@@]7=C([C@H](C)OC)N=CC(N8CCN(C)CC8)=C7
PF-07265807,,2412356-57-9,591.57,c-Met/HGFR; TAM Receptor,Protein Tyrosine Kinase/RTK,"PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer[1].",C29H27F2N7O5,DMSO : 200 mg/mL (338.08 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC[C@@H](C)NC1=NNC2=NC=CC(OC3=C(C=C(C=C3)NC(C(C(N4C5=CC=C(C=C5)F)=O)=CN(C(C)C)C4=O)=O)F)=C12
Irinotecan (hydrochloride),(+)-Irinotecan (hydrochloride); CPT-11 (hydrochloride); VAL-413,100286-90-6,623.14,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer[1].,C33H39ClN4O6,DMSO : 125 mg/mL (200.60 mM; Need ultrasonic); H2O : 3.33 mg/mL (5.34 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.[H]Cl
PR-104,,851627-62-8,579.27,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A[1].",C14H20BrN4O12PS,DMSO : 100 mg/mL (172.63 mM; Need ultrasonic); H2O : 31.25 mg/mL (53.95 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(NCCOP(O)(O)=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1N(CCBr)CCOS(=O)(C)=O
Brepocitinib,PF-06700841,1883299-62-4,389.4,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Brepocitinib (PF-06700841) is a potent dual  Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1].",C18H21F2N7O,DMSO : 125 mg/mL (321.01 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,O=C([C@H]1C(F)(F)C1)N2C3CN(C4=NC(NC5=CN(C)N=C5)=NC=C4)CC2CC3
Cerdulatinib (hydrochloride),PRT062070 (hydrochloride); PRT2070 (hydrochloride),1369761-01-2,482.0,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies[1][2].",C20H28ClN7O3S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 20 mg/mL (41.49 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Phase 3,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O.Cl
Erlotinib,CP-358774; NSC 718781; OSI-774,183321-74-6,393.44,Autophagy; EGFR,Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C22H23N3O4,DMSO : 3.94 mg/mL (10.01 mM; ultrasonic and warming and heat to 40°C),10mM,Cancer,Launched,C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
Lisavanbulin (dihydrochloride),BAL-101553 (dihydrochloride),1387574-54-0,588.49,Checkpoint Kinase (Chk); Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].",C26H31Cl2N9O3,DMSO : 125 mg/mL (212.41 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN.Cl.Cl
Exatecan (mesylate),DX8951f,169869-90-3,531.55,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.",C25H26FN3O7S,H2O : 10 mg/mL (18.81 mM; ultrasonic and warming and heat to 60°C); DMSO : 3.45 mg/mL (6.49 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=S(C)(O)=O.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O
Simotinib,,944258-89-3,500.95,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].",C25H26ClFN4O4,DMSO : 100 mg/mL (199.62 mM; Need ultrasonic),10mM,Cancer,Launched,COC1=CC2=C(C(NC(C=C3)=CC(Cl)=C3F)=NC=N2)C=C1OCCN4CC5(CC5)C6(OCCO6)C4
Pacritinib,SB1518,937272-79-2,472.58,FLT3; JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).,C28H32N4O3,DMSO : 10 mg/mL (21.16 mM; ultrasonic and warming and heat to 60°C); 0.1 M HCl : 2 mg/mL (4.23 mM; Need ultrasonic); 1 M HCl : ≥ 100 mg/mL (211.60 mM),10mM,Cancer,Launched,C1(COC/C=C/COCC2=C(OCCN3CCCC3)C=CC4=C2)=CC=CC(C5=N/C(NC=C5)=N\4)=C1
Rezivertinib,BPI-7711,1835667-12-3,486.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity[1][2].",C27H30N6O3,DMSO : 125 mg/mL (256.90 mM; Need ultrasonic),10mM,Cancer,Phase 3,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1OCCN(C)C)=O
Dovitinib,CHIR-258; TKI258,405169-16-6,392.43,c-Fms; c-Kit; FGFR; FLT3; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity[1][2].",C21H21FN6O,DMSO : 23.33 mg/mL (59.45 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C1NC(C=CC=C2F)=C2C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
Apitolisib,GDC-0980; GNE 390; RG 7422,1032754-93-0,498.6,Apoptosis; mTOR; PI3K,Apoptosis; PI3K/Akt/mTOR,"Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a Ki of 17 nM for mTOR.",C23H30N8O3S,DMSO : 14.29 mg/mL (28.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@@H](C(N1CCN(CC1)CC2=C(C3=NC(C4=CN=C(N=C4)N)=NC(N5CCOCC5)=C3S2)C)=O)O
XL 999,Tyrosine kinase-IN-1,705946-27-6,445.53,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer[1].",C26H28FN5O,DMSO : 50 mg/mL (112.23 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 2,O=C1NC2=C(C=C(NC3CCN(CC)CC3)C=C2)/C1=C(C4=CC=CC(F)=C4)/C5=NC=C(C)N5
Almonertinib,HS-10296,1899921-05-1,525.64,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer[1][2].",C30H35N7O2,DMSO : 80 mg/mL (152.20 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2
Fedratinib,TG-101348; SAR 302503,936091-26-8,524.68,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].",C27H36N6O3S,DMSO : 125 mg/mL (238.24 mM; Need ultrasonic),10mM,Cancer,Launched,O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
Terfenadine,(±)-Terfenadine; MDL-991,50679-08-8,471.67,Apoptosis; Caspase; Histamine Receptor; Na+/Ca2+ Exchanger; Potassium Channel,Apoptosis; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling,"Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].",C32H41NO2,DMSO : ≥ 50 mg/mL (106.01 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer; Inflammation/Immunology; Endocrinology,Launched,OC(C1=CC=C(C(C)(C)C)C=C1)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2
BOLD-100,NKP-1339; IT-139; KP-1339,197723-00-5,502.14,Apoptosis; DNA/RNA Synthesis,Apoptosis; Cell Cycle/DNA Damage,"BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].",C14H12Cl4N4NaRu,DMSO : ≥ 59 mg/mL (117.50 mM),10mM,Cancer,Phase 2,[Cl-][Ru+3]([Cl-])([Cl-])([N]1=CC2=C(N1)C=CC=C2)([N]3=CC4=C(N3)C=CC=C4)[Cl-].[Na+]
C188-9,TTI-101,432001-19-9,471.52,Apoptosis; STAT,Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt,"C188-9 (TTI-101) is a STAT3 inhibitor, with a Kd of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces apoptosis in AML cell lines and primary samples and inhibits colony formation by primary AML blasts[1][2][3][4].",C27H21NO5S,DMSO : 25 mg/mL (53.02 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=S(C1=CC=C(OC)C=C1)(NC2=C3C=CC=CC3=C(O)C(C4=C5C=CC=CC5=CC=C4O)=C2)=O
Itacnosertib (hydrochloride),TP-0184 (hydrochloride),2409543-84-4,505.01,Akt; Anaplastic lymphoma kinase (ALK); FLT3; JAK; mTOR; PI3K; STAT; TGF-beta/Smad; TGF-β Receptor,Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad,"Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity[1][2].",C26H29ClN8O,DMSO : 5.56 mg/mL (11.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1CCN(C2=CC=C(NC3=NC=CC(NC4=CC=CN=C4C5=NC=CC=C5)=N3)C=C2OC)CC1.[H]Cl
Povorcitinib (phosphate),INCB54707 (phosphate),1637677-33-8,605.45,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1)[1].,C23H25F5N7O5P,DMSO : 100 mg/mL (165.17 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,O=P(O)(O)O.N#CCC1(N2C=C(C3=C(C)NN=C3C)C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1
Umbralisib,TGR-1202; RP5264,1532533-67-7,571.55,Casein Kinase; PI3K,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach[1][2][3][4].",C31H24F3N5O3,DMSO : 25 mg/mL (43.74 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16
AEE788,NVP-AEE 788,497839-62-0,440.58,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"AEE788 is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively.",C27H32N6,DMSO : 50 mg/mL (113.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](C1=CC=CC=C1)NC2=C(C=C3C(C=C4)=CC=C4CN5CCN(CC)CC5)C(N3)=NC=N2
Camptothecin-20(S)-O-propionate,Camptothecin-20-O-propionate,194414-69-2,404.42,Topoisomerase,Cell Cycle/DNA Damage,"Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor[1][2][3].",C23H20N2O5,DMSO : 9.09 mg/mL (22.48 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1[C@](CC)(C2=C(C(N3CC4=CC5=CC=CC=C5N=C4C3=C2)=O)CO1)OC(CC)=O
Roginolisib,MSC2360844; IOA-244,1305267-37-1,526.58,PI3K,PI3K/Akt/mTOR,"Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases[1].",C26H27FN4O5S,DMSO : 100 mg/mL (189.90 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6
MRTX0902,,2654743-22-1,388.47,Ras; SOS1,GPCR/G Protein; MAPK/ERK Pathway,MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10)[1].,C22H24N6O,DMSO : 12.5 mg/mL (32.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,C[C@H](C1=C(C(C#N)=CC=C1)C)NC2=NN=C(C)C3=C2C=C(N4CCOCC4)N=C3
Migoprotafib,GDC-1971,2377352-49-1,454.53,ERK; p38 MAPK; Phosphatase; SHP2,MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].",C25H26N8O,DMSO : 100 mg/mL (220.01 mM; Need ultrasonic),10mM,Cancer,Phase 1,N[C@H]1C2(CCN(C3=CN=C(C(N4C5=CC=CN=C5CCC4)=NN6)C6=N3)CC2)OC7=CC=CC=C71
KRN-633,,286370-15-8,416.86,VEGFR,Protein Tyrosine Kinase/RTK,"KRN-633 is a potent VEGFR inhibitor with IC50s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. ",C20H21ClN4O4,DMSO : 25 mg/mL (59.97 mM; Need ultrasonic),10mM,Cancer,Phase 1,ClC1=CC(OC2=NC=NC3=CC(OC)=C(C=C32)OC)=CC=C1NC(NCCC)=O
MK-8033,,1001917-37-8,471.53,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs)[1][2].",C25H21N5O3S,DMSO : ≥ 46 mg/mL (97.55 mM),10mM,Cancer,Phase 1,O=S(NCC1=CC=CC=N1)(CC2=CC=C3C(C(C4=CC(C5=CN(N=C5)C)=CN=C4C=C3)=O)=C2)=O
Tersolisib,STX-478,2883540-92-7,401.29,PI3K,PI3K/Akt/mTOR,STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research[1].,C16H12F5N5O2,DMSO : 100 mg/mL (249.20 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NC=C(C=N1)NC(N[C@H](C2=C(C3=CC(F)=CC(F)=C3O2)C)C(F)(F)F)=O
Sorafenib (tosylate),Bay 43-9006 (tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib tosylate (Bay 43-9006 tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib tosylate induces autophagy and apoptosis. Sorafenib tosylate has anti-tumor activity. Sorafenib tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,DMSO : ≥ 100 mg/mL (156.98 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
Flubendazole,,31430-15-6,313.28,Apoptosis; Autophagy; MDM-2/p53; Microtubule/Tubulin; Parasite; STAT,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; JAK/STAT Signaling; Stem Cell/Wnt,"Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites[1][2].",C16H12FN3O3,DMSO : 4.17 mg/mL (13.31 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C(OC)NC1=NC2=CC=C(C(C3=CC=C(F)C=C3)=O)C=C2N1
GSK2646264,,1398695-47-0,374.48,Aurora Kinase; GSK-3; JAK; LRRK2; Src; Syk; VEGFR,Autophagy; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin[1].",C24H26N2O2,DMSO : 50 mg/mL (133.52 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 1,CC1=CC(COC2=C(C3=CC=C4CCNCCC4=C3)C(OC)=CC=C2)=NC=C1
Alpelisib,BYL-719,1217486-61-7,441.47,PI3K,PI3K/Akt/mTOR,"Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].",C19H22F3N5O2S,DMSO : 83.33 mg/mL (188.76 mM; Need ultrasonic),10mM,Cancer,Launched,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
RGB-286638,,784210-87-3,618.55,CDK; GSK-3; JAK; MEK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of  3, 5, 50, and 54 nM.",C29H37Cl2N7O4,H2O : 25 mg/mL (40.42 mM; Need ultrasonic); DMSO : ≥ 150 mg/mL (242.50 mM),10mM,Cancer,Phase 1,O=C(NN1CCOCC1)NC2=CC=CC(C3=C4C(C5=CC=C(CN6CCN(CCOC)CC6)C=C5)=NN3)=C2C4=O.[H]Cl.[H]Cl
Tivumecirnon,FLX475,2174938-78-2,543.41,CCR,GPCR/G Protein; Immunology/Inflammation,"Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity[1][2][3][4].",C24H27Cl2F3N6O,DMSO : 100 mg/mL (184.02 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,C[C@H](C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(N4CC([C@H]5CCCN(C5)CCO)C4)=CN=C3C(C(F)(F)F)=N2
Lomefloxacin (hydrochloride),SC47111A (hydrochloride); NY-198 (hydrochloride),98079-52-8,387.81,Antibiotic; Apoptosis; Bacterial; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma [1][2][3][4][5][6].",C17H20ClF2N3O3,H2O : 7.14 mg/mL (18.41 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Endocrinology,Launched,CCN(C=C(C(O)=O)C1=O)C(C1=CC(F)=C2N(CCN3)CC3C)=C2F.Cl
Masitinib,AB1010,790299-79-5,498.64,Apoptosis; c-Kit; FAK; FGFR; PDGFR; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity[1][2][4].",C28H30N6OS,DMSO : 100 mg/mL (200.55 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
Linsitinib,OSI-906,867160-71-2,421.49,IGF-1R; Insulin Receptor,Protein Tyrosine Kinase/RTK,"Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively[1].",C26H23N5O,DMSO : 50 mg/mL (118.63 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Phase 3,O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1
Voreloxin (Hydrochloride),SNS-595 Hydrochloride; Vosaroxin Hydrochloride; AG 7352 Hydrochloride,175519-16-1,437.9,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Voreloxin Hydrochloride is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.",C18H20ClN5O4S,DMSO : 2 mg/mL (4.57 mM; ultrasonic and warming and heat to 60°C); H2O : 2 mg/mL (4.57 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 3,[H]Cl.O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
Neratinib (maleate),HKI-272 (maleate),915942-22-2,673.11,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively[1].",C34H33ClN6O7,DMSO : 250 mg/mL (371.41 mM; Need ultrasonic),10mM,Cancer,Launched,OC(/C=C\C(O)=O)=O.CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(Cl)=C(C=C3)OCC4=CC=CC=N4)=C(C#N)C=N2
BFH772,,890128-81-1,439.39,VEGFR,Protein Tyrosine Kinase/RTK,"BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM[1].",C23H16F3N3O3,DMSO : 100 mg/mL (227.59 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC=CC3=CC(OC4=NC=NC(CO)=C4)=CC=C32
Nifuratel,NF 113; SAP 113; Methylmercadone,4936-47-4,285.28,Antibiotic; Apoptosis; Bacterial; Fungal; Interleukin Related; Parasite; STAT; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt,"Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases[1][2][3][4][5][6][7][8].",C10H11N3O5S,H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (175.27 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2
Baricitinib,LY3009104; INCB028050,1187594-09-7,371.42,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.",C16H17N7O2S,DMSO : 25 mg/mL (67.31 mM; Need ultrasonic and warming),10mM,Inflammation/Immunology,Launched,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1
Merestinib dihydrochloride,LY2801653 (dihydrochloride),1206801-37-7,625.45,c-Met/HGFR; Discoidin Domain Receptor; FLT3; ROS Kinase,Protein Tyrosine Kinase/RTK,"Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].",C30H24Cl2F2N6O3,DMSO : ≥ 100 mg/mL (159.88 mM),10mM,Cancer,Phase 2,[H]Cl.[H]Cl.O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
(R)-Lisofylline,(R)-Lisophylline,100324-81-0,280.32,STAT,JAK/STAT Signaling; Stem Cell/Wnt,"(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research[1][2].",C13H20N4O3,DMSO : 100 mg/mL (356.74 mM; Need ultrasonic),10mM,Metabolic Disease; Inflammation/Immunology,Phase 2,O=C(N1CCCC[C@H](O)C)N(C)C2=C(N(C)C=N2)C1=O
Gemcitabine (hydrochloride),LY 188011 (hydrochloride),122111-03-9,299.66,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H12ClF2N3O4,H2O : 25 mg/mL (83.43 mM; Need ultrasonic); DMSO : 62.5 mg/mL (208.57 mM; ultrasonic and warming and heat to 60°C); DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl
CC-115,,1228013-15-7,336.35,DNA-PK; mTOR,Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"CC-115 is a potent and dual  DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.",C16H16N8O,DMSO : 20 mg/mL (59.46 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
Ilginatinib,NS-018,1239358-86-1,389.43,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).",C21H20FN7,DMSO : 100 mg/mL (256.79 mM; Need ultrasonic),10mM,Cancer,Phase 2,CN1N=CC(C2=CC(N[C@H](C3=CC=C(F)C=C3)C)=NC(NC4=NC=CN=C4)=C2)=C1
AZ7550 Mesylate,AZ7550 trimesylate salt,2319837-99-3,773.9,Drug Metabolite; EGFR; IGF-1R,JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.,C30H43N7O11S3,DMSO : 25 mg/mL (32.30 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Phase 1,CN1C=C(C2=NC(NC3=CC(NC(C=C)=O)=C(N(CCNC)C)C=C3OC)=NC=C2)C4=CC=CC=C41.O=S(O)(C)=O.O=S(O)(C)=O.O=S(O)(C)=O
Pirarubicin (Hydrochloride),THP Hydrochloride,95343-20-7,664.1,Antibiotic; Autophagy; Bacterial; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.",C32H38ClNO12,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 20.83 mg/mL (31.37 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O.Cl
Tegafur,FT 207; NSC 148958,17902-23-7,200.17,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU proagent used in the treatment of cancers; is a component of tegafur-uracil.,C8H9FN2O3,DMSO : ≥ 48 mg/mL (239.80 mM); H2O : ≥ 20 mg/mL (99.92 mM),10mM,Cancer,Launched,O=C1NC(C(F)=CN1C2OCCC2)=O
Osimertinib,AZD-9291; Mereletinib,1421373-65-0,499.61,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].",C28H33N7O2,DMSO : 100 mg/mL (200.16 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Vidarabine,Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine,5536-17-4,267.25,Antibiotic; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Cell Cycle/DNA Damage,Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3].,C10H13N5O4,DMSO : 50 mg/mL (187.09 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Infection,Launched,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1
Lonidamine,AF-1890; Diclondazolic Acid; DICA,50264-69-2,321.16,Apoptosis; Hexokinase; Mitochondrial Metabolism; Parasite,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis[1][2][3].",C15H10Cl2N2O2,DMSO : 50 mg/mL (155.69 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O
Vorolanib,CM082; X-82,1013920-15-4,439.48,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895)[1][2].",C23H26FN5O3,DMSO : 27 mg/mL (61.44 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C1/C(C2=CC(F)=CC=C2N1)=C/C(NC(C)=C3C(N[C@@H]4CN(C(N(C)C)=O)CC4)=O)=C3C
Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
